Japan’s foray into regenerative medicine takes on added importance for a nation wrestling with age, stagnation, and its place ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of ...

The discovery of an alternative method of producing induced human stem cells will affect the ethical ... announced that they had independently managed to produce induced Pluripotent Cells (iPC) from ...

Over the last decades, several innovations have advanced the understanding of human biology and diseases. From the development of induced pluripotent stem ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf ...

Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment ...

Additional information, including the accepted abstracts, can be accessed on the EULAR 2025 Congress website. Presentation materials will be made available in the Science section under Scientific ...

A cell therapy for regenerating broken spinal cord using lab-grown neurons enters human trials for the first time.

A reference genome of the near-extinct northern white rhinoceros can indicate the quality of rhino stem cells that can ...

Osteogenic differentiation is essential for bone development, metabolism, and repair; however, the underlying regulatory relationships among genes remain poorly understood. To elucidate the ...

A research team led by Associate Professor Makoto Ikeya in the Department of Clinical Application at Kyoto University has ...

HSCN1cl10 cells, like the multiclonal HSCN1 cells, expressed the constitutively active Notch1 protein and grew continuously in the combination of factors consisting of 100 ng/ml each of SCF ...